Long Term Hormone Therapy Raises Risk of Cardiovascular Death

If you have been on hormone therapy (androgen deprivation therapy, ADT) for significant periods of time, e.g. greater than six months, this blog has some valuable information and recommendation for you. A new study reports that long-term exposure to androgen deprivation therapy (ADT), a common treatment for prostate cancer, is associated with worse cardiorespiratory fitness and a higher risk of cardiovascular death. Men who received ADT therapy for more than six months were ultimately found to have a nearly four times higher risk of death than those not exposed to the therapy. The scientists from Brigham and Women’s Hospital and Dana Farber Cancer Institute, both in Boston, noted that further research will be necessary to determine whether cardiovascular-targeted interventions, like exercise, might help reduce cardiovascular risk in prostate cancer patients undergoing long-term ADT. For us with prostate cancer, physical exercise and strengthening are both valuable habits.

For a full article, see the Jan. 11th, 2021 Prostate Cancer News Today.

Five Things to Know About PSMA-PET Scanning

A recent post on this website discussed the newly approved PSMA-PET scan for the detection of smaller areas of metastatic cancer. Here are five important pieces of information from the Prostate Cancer Foundation about the recently approved gallium-68 PSMA-PET scan. They are: 1) exactlywhat is PSMA-PET scanning? 2) how does it work? 3) is the radiation in PSMA-PET scans dangerous? 4) is PSMA-PET right for every cancer patient? and, 5) where can I get a PSMA-PET scan?. See the following link.